<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="/images/favicon.png" type="image/x-icon">
  <title>Neonatal Hyperbilirubinemia</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>
      
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


    <h1>Neonatal Hyperbilirubinemia</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <div class="outline2">

      <input type="radio" name="control-2" id="show-2">
      <label for="show-2">Show Outline</label>
      <input type="radio" name="control-2" id="hide-2">
      <label for="hide-2">Hide Outline</label>
      <div class="contents">
         <ol>
            <li><a href="#header-1">Overview</a></li>
            <li><a href="#header-2">Bilirubin Metabolism</a></li>
            <li><a href="#header-3">Classification</a></li>
            <ul>
              <li><a href="#heading-3-1">Physiologic Jaundice</a></li>
              <li><a href="#heading-3-2">Non Physiologic Jaundice</a></li>
            </ul>
            <li><a href="#header-4">Common Non-Physiological Causes</a></li>
            <ul>
              <li><a href="#heading-4-1">Iso-Immune Haemolytic Diseases</a></li>
              <li><a href="#heading-4-2">G6PD Deficiency</a></li>
              <li><a href="#heading-4-3">Breast Milk Jaundice</a></li>
            </ul>
            <li><a href="#header-5">Bilirubin Toxicity</a></li>
            <li><a href="#header-6">Management</a></li>
         </ol>
      </div>
     <div>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Overview</a>
          </h2>
        </header>
        <div class='body'>
          <p>This is an elevation in serum bilirubin</p>
          <p>Hyperbilirubinemia exists in 2 forms</p>
          <ul>
            <li>Unconjugated </li>
            <li>Conjugated     </li>
          </ul>
          <p>The management concerns are:</p>
          <ul>
            <li>Bilirubin encephalopathy -unconjugated </li>
            <li>Severity of underlying illness-conjugated</li>
          </ul>
          <p>Hyperbilirubinaemia is very common in the 1st week of life</p>
          <p>Occurring in 60% of term babies and 80% of preterm babies</p>

          <h4>Specific issues in Management</h4>
          <ul>
            <li>Level: What is the serum bilirubin level? </li>
            <li>Type: Is it conjugated or un-conjugated?</li>
            <li>Aetiology: What is the specific cause of the NNH?</li>
            <li>Physiological vs. Non Physiological</li>
            <li>For non-physiological: Increased production/ Decreased Secretion</li>
            <li>Severity: Encephalopathy imminent, present or unlikely?</li>
            <li>Treatment: What is the choice of treatment?</li>
            <li>Complications: What further anticipatory care is required?</li>
            <li>Prevention: What preventive measure is needed?</li>
          </ul>

          <h4>Definitions</h4>
          <ul>
            <li>NNH is an elevation of serum bilirubin > 17Âµmol/L or > 1mg/dl </li>
            <li>Jaundice is yellowish discoloration of skin and sclera secondary to accumulation of bilirubin in blood.</li>
            <li>Jaundice normally occurs when serum bilirubin is â‰¥ 6mg/dl. (eye of the beholder)</li>
          </ul>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Bilirubin Metabolism</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Between 17-30 weeks the ability of the fetal liver to clear bilirubin is severely limited because UDP-Glucoronosyl transferase activity is only 0.1% of adult values</li>
              <li>This increases tenfold to 1% btw 30-40wks</li>
              <li>After birth it increases exponentially reaching adult levels in 6-14wks independent of GA</li>
              <li>The major route of fetal bilirubin excretion is across the placenta</li>
            </ul>

            <figure>
              <img src="../figures/nn-hyperbili (1).png" alt="">
              <figcaption>1g of Haemoglobin yields 35mg of bilirubin  </figcaption>
            </figure>

            <figure>
              <img src="../figures/nn-hyperbili (3).png" alt="">
              <figcaption>Biliverdin reductase </figcaption>
            </figure>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Classification </a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>Physiologic/Non-physiologic (pathologic)</li>
            <li>Conjugated/unconjugated</li>
            <ul>
              <li>	Once more than 20% of total bilirubin is conjugated, it is classified as conjugated. </li>
            </ul>
          </ul>

          <h4>Commonest Causes in UITH</h4>
          <ul>
            <li>Physiologic</li>
            <li>Non-physiologic</li>
            <ul>
              <li>ABO incompatibility</li>
              <li>G6PD deficiency</li>
              <li>Rh incompatibility</li>
              <li>Infections (sepsis, congenital, hepatitis)</li>
            </ul>
          </ul>

          <section id='heading-3-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-1'>Physiologic Jaundice</a>
              </h3>
            </header>
            <div class='body'>
               <p>Jaundice attributable to immaturity of the newborn organ and systems</p>
               <h4>CRITERIA FOR PHYSIOLOGIC JAUNDICE</h4>
               <ul>
                <li>Onsetâ€” Not before 24hours</li>
                <li>Daily riseâ€” Does not exceed 5mg/dl</li>
                <li>Peak levelâ€” 12mg/dl in Term and 15mg/dl in Preterms</li>
                <li>Peak durationâ€” 3rd â€“ 5th day in Term; 5th â€“ 7th in Preterms</li>
                <li>Durationâ€” 7-10days in term babies and 2-3weeks in preterms</li>
                <li>Conjugated fractionâ€” Does not exceed 10% of total</li>
               </ul>

               <h4>MECHANISM OF PHYSIOLOGIC JAUNDICE</h4>
               <ul>
                <li>Increased Bilirubin load on liver cell</li>
                <ul>
                  <li>Increase RBC volume, decrease RBC survival, increased E-H circulation</li>
                </ul>
                <li>Defective hepatic uptake of bilirubin</li>
                <ul>
                  <li>Decrease Ligandin (Y-protein)</li>
                </ul>
                <li>Defective bilirubin conjugation</li>
                <ul>
                  <li>Decrease activity of transferase enzyme (UDPGT â€“ Uridyldiglucoronosyl Transferase)</li>
                </ul>
                <li>Defective bilirubin excretion.</li>
                <ul>
                  <li>Excretion impaired but not rate-limiting</li>
                </ul>
               </ul>

               <h4>Major Reasons why a baby will have physiologic jaundice</h4>
               <ol>
                <li>Increased red cell mass</li>
                <li>Reduced red cell survival</li>
                <li>Reduction in activity of UDPGT</li>
               </ol>
               <p>In addition </p>
               <ul>
                <li>Infants lack the bacterial flora necessary to convert bilirubin to urobilinogen, so unconjugated bilirubin persists throughout the entire GI tract.</li>
                <li>Also, meconium contains large amounts of unconjugated bilirubin </li>
                <li>Intensity and duration of physiologic jaundice varies widely</li>
               </ul>
            </div>
          </section>

          <section id='heading-3-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-2'>Non-Physiologic Jaundice</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Jaundice due to other aggravating factors</li>
                <li>Failure to meet at LEAST ONE of the CRITERIA for Physiological HB</li>
                <li>Note however that in majority of cases etiology is unknown</li>
               </ul>

               <h4>CAUSES OF UNCONJUGATED NON-PHYSIOLOGICAL HYPERBILIRUBINAEMIA</h4>
               <ol>
                <li>Over Production of Bilirubin</li>
                <p>Haemolytic </p>
                <ul>
                  <li>Antibody mediated haemolysis </li>
                  <ul>
                    <li>ABO Incompatibility, Rh Incompatibility</li>
                    <li>Minor blood group incompatibility (anti-E & c, anti-Kell)</li>
                  </ul>
                  <li>Red Cell Enzyme defects</li>
                  <ul>
                    <li>G-6-P-D, Pyruvate kinase deficiency</li>
                  </ul>
                  <li>Red Cell Membrane defects</li>
                  <li>Hereditary spherocytosis, Elliptocytosis</li>
                </ul>

                <p>Extravascular Blood</p>
                <ul>
                  <li>Bruises, IVH,  Cephalohaematoma, Subgaleal hematoma</li>
                </ul>

                <p>Drug Induced Hemolysis</p>
                <ul>
                  <li>Vitamin K3 induced haemolysis</li>
                </ul>

                <p>Polycythaemia</h4>
                
                <li>Conjugation Defects</li>
                <p>Inherited reduction in glucoronosyl transferase </p>
                <ul>
                  <li>Familial non-haemolytic jaundice (Crigler-Najjar type I)</li>
                  <ul>
                    <li>Autosomal recessive, Severe</li>
                  </ul>
                  <li>Familial non-haemolytic jaundice (Crigler-Najjar type II)</li>
                  <ul>
                    <li>Autosomal dominant, milder cause</li>
                  </ul>
                </ul>
                <p>Abnormal glucoronyl transferase</p>
                <ul>
                  <li>Gilbert Syndrome</li>
                </ul>
                <p>Acquired inhibition of glucorosyl tranferase</p>
                <ul>
                  <li>Breast milk jaundice (5-b-pregnane-3a,20-b-diol or nonesterified long chain fatty acids) glucoronidase in some milk</li>
                </ul>
               </ol>

               <h4>CAUSES OF CONJUGATED NON-PHYSIOLOGICAL HYPERBILIRUBINAEMIA</h4>
               <ol>
                <li>Decreased Secretion</li>
                <p>Impaired transport of the hepatocytes</p>
                <ul>
                  <li>Congenital transport defect: Dubin-Johnson, Rotor syndrome</li>
                  <li>Hepatocellular damage secondary to metabolic disorders (galactosaemia)</li>
                </ul>
                <p>Obstruction of bile flow:</p>
                <ul>
                  <li>Biliary atresia, extrinsic obstruction (intestinal obstruction) choledochal cyst</li>
                </ul>
                <li>Mixed </li>
                <ul>
                  <li>Prenatal infections</li>
                  <li>Sepsis</li>
                  <li>Multi-system disorders</li>
                  <ul>
                    <li>IDM, Perinatal asphyxia</li>
                  </ul>
                </ul>
               </ol>
            </div>
          </section>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Common Non-Physiological Causes</a>
          </h2>
        </header>
        <div class='body'>
          <section id='heading-4-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-1'>Iso-Immune Haemolytic Diseases</a>
              </h3>
            </header>
            <div class='body'>
               <h4>ABO Haemolytic Disease</h4>
               <p>Description </p>
               <ul>
                <li>Action of maternal anti-A or anti-B antibodies on fetal erythrocytes of the corresponding blood group</li>
                <li>It is the commonest cause of Non-physiologic hyperbilirubinaemia</li>
               </ul>
               <p>Pathogenesis</p>
               <ul>
                <li>Group O subjects have Anti-A or Anti-B antibodies of the IgG and IgM subclass in their plasma.</li>
                <li>In the event of a pregnancy with appropriate set up the IgG anti-A or anti-B antibodies cross the placenta to attack the fetal RBC</li>
                <li>These results in damage to erythrocytes and their destruction by the RES</li>
                <li>Attempts at repairing the partially damaged erythrocytes results in the formation of microspherocytes.</li>
               </ul>
               <p>Characteristics of ABO disease</p>
               <ul>
                <li>May affect first child</li>
                <li>Degree of severity is similar among siblings</li>
                <li>Early non-physiological jaundice</li>
                <li>Anaemia may be mild or non-existent</li>
               </ul>
               <p>Criteria for diagnosis</p>
               <ul>
                <li>Unconjugated hyperbilirubinaemia</li>
                <li>Jaundice during the first 24 hours</li>
                <li>An A or B baby of an O mother</li>
                <li>Increased number of microspherocytes</li>
                <li>Positive Coombs test </li>
                <li>Increased RBC production in the blood </li>
                <li>Reticulocytosis</li>
               </ul>


               <h4>Rhesus incompatibility</h4>
               <p>Description </p>
               <ul>
                <li>Due to action of maternal anti-D antibodies on the Rhesus antigen of fetal erythrocytes </li>
               </ul>
               <p>Pathogenesis</p>
               <ul>
                <li>It is due to the entry of fetal cells into the maternal circulation</li>
                <li>As few as 0.05-0.1ml of cells is enough to produce immunization</li>
                <li>Following sensitization, Rh-negative subjects produce anti-D antibodies of the IgG class</li>
                <li>The antibodies crosses the placenta to attack fetal RBC</li>
                <li>The anti-body coated RBC is removed by the spleen in the fetus</li>
                <li>Before birth the main danger is anaemia</li>
                <li>After birth it is severe hyperbilirubinaemia</li>
                <li>In utero there is increase rate of erythrocyte production-</li>
                <ul>
                  <li>Reticulocytosis and Nrbc</li>
                </ul>
                <li>Resulting in increased extramedullary erythropoiesis â€“ liver, spleen and lungs</li>
                <li>Most severe infants manifest hydrops fetalis</li>
                <li>Massive edema, ascites and pleural effusion. </li>
                <li>Can lead to baby being stillborn</li>
               </ul>
               <p>Characteristics of Rh disease</p>
               <ul>
                <li>Spares the first pregnancy</li>
                <li>Increasing degree of severity with subsequent pregnancies</li>
                <li>Early non-physiological jaundice</li>
                <li>Anaemia usually profound</li>
                <li>Hepatosplenomegally</li>
               </ul>
               <p>Criteria for diagnosis</p>
               <ul>
                <li>Unconjugated hyperbilirubinaemia</li>
                <li>Jaundice during the first 24 hours</li>
                <li>Rh-Positive baby  of Rh-negative mother</li>
                <li>Low Hb or PCV </li>
                <li>Strongly positive Coombs test </li>
                <ul>
                  <li>Reticulocytosis</li>
                  <li>Elevated levels of carboxyhaemoglobin</li>
                </ul>
               </ul>
               
               <p>Prevention</p>
               <ul>
                <li>Focuses primarily on the administration of anti-D immunoglobulin to mothers after delivery or abortion of an Rh-positive fetus.</li>
                <li>This is in the form of human anti-D concentrate called RhoGAM (300ug)</li>
                <li>Acid elution test of Kleihauer and Betke can be used to detect cases of massive transplacental haemorrhage that will require larger doses of anti-D immunoglobulin</li>
               </ul>
            </div>
          </section>

          <section id='heading-4-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-2'>G6PD Deficiency</a>
              </h3>
            </header>
            <div class='body'>
               <h4>Pathogenesis</h4>
               <ul>
                <li>RBC are liable to damage from oxidants</li>
                <li>Resulting in the formation of oxidized Hb which precipitates as Heinz  bodies</li>
                <li>G6PD necessary for protecting the RBC from this oxidative stress</li>
                <ul>
                  <li>Reduced GSH donates H- to reduce Oxidized Hb</li>
                  <li>The Oxidized GSSH is reduced by NADPH</li>
                  <li>The NADPH is derived from the HMP shunt at the G-6-PD step</li>
                </ul>
               </ul>
               <h4>Precipitants of acute haemolysis include</h4>
               <ul>
                <li>Drugs</li>
                <ul>
                  <li>Primaquine</li>
                  <li>Nitrofurantoin</li>
                  <li>Sulfonamides</li>
                  <li>Nalidixic Acid</li>
                  <li>Methylene blue</li>
                </ul>
                <li>Infections</li>
                <li>Naphthalene balls</li>
               </ul>
            </div>
          </section>

          <section id='heading-4-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-3'>Breast Milk Jaundice</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>There is significant and prolonged elevation of un-conjugated Br</li>
                <li>Incidence is very low</li>
                <li>Usually a diagnosis of exclusion</li>
                <li>Thought to be due to </li>
                <ul>
                  <li>The inhibition of the Glucoronosyl transferase by a steroid 3-a,20Î² pregnanediol</li>
                  <li>Excess lipase librating FFA which interfere with protein binding and conjugation</li>
                </ul>
               </ul>

               <h4>Clinical course</h4>
               <ul>
                <li>Usually noticed from the 5th day </li>
                <li>Continues to increase to the second week</li>
                <li>Essentially un-conjugated</li>
                <li>Has now been  reported to be associated with Br Encephalopathy (previously, it was thought that it couldnâ€™t result in encephalopathy)</li>
               </ul>
               
            </div>
          </section>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Bilirubin Toxicity</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Kernicterusâ€” pathologistâ€™s term </li>
              <li>Bilirubin encephalopathyâ€” general term</li>
              <li>Accumulates in the basal ganglia, hippocampus, cranial nerve nuclei, cerebellar nuclei and inferior olivary nuclei</li>
              <li>Original yellow deposits fade leaving dead neurons</li>
              <li>Results in permanent brain injury</li>
            </ul>

            <h4>Bilirubin Encephalopathy</h4>
            <p>Secondary to toxic effects of Br Acid on neurons </p>
            <p>Determinants of BE</p>
            <ul>
              <li>Concentration of Serum Unconjugated Br</li>
              <li>Concentration of serum albumin</li>
              <li>Bilirubin binding by albumin</li>
              <li>pH</li>
              <li>Integrity of the blood brain barrier</li>
              <li>Gestational Age</li>
            </ul>
            <p>Neuronal Injury</p>
            <ul>
              <li>BG, Brain stem nuclei for occulomotor function and brain stem auditory (cochlear) nuclei</li>
            </ul>
            <p>Staging</p>
            <ul>
              <li>Stage 1â€” Poor Moro, decreased tone, lethargy, poor suck, vomiting, High pitch cry</li>
              <li>Stage 2â€” Hypertonia, retrocollis, opisthotonus, oculo-gyric crises, paralysis of upward gaze. Many infants die at this stage</li>
              <li>Stage 3â€” Temporal evolution in tone: Hypernormal, Hypotonia, usually begins after the first week</li>
              <li>Stage 4â€” Chronic sequelae</li>
            </ul>

            <h4>Chronic Postkernicteric Encephalopathy</h4>
            <p>Includes cerebral palsy associated with:		</p>
            <ul>
              <li>Paralysis of upward gaze	</li>
              <li>High frequency hearing loss</li>
              <li>Athetosis					</li>
              <li>Mental retardation</li>
            </ul>
            <p>Evidence of neurological signs = permanent damage</p>

            <h4>BIND Score</h4>
            <p>This BIND assessment can also be used as part of the comprehensive assessment or used exclusively with infants with known hyperbilirubinemia to evaluate progression of symptoms of bilirubin toxicity.  </p>
            <figure>
              <img src="../figures/nn-hyperbili (1).jpg" alt="">
              <figcaption> </figcaption>
            </figure>
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Management </a>
          </h2>
        </header>
        <div class='body'>
          <section id='heading-6-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-1'>History</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>When did the jaundice start? </li>
                <li>How has it been progressing? Jaundice progresses from face downwards, by the time jaundice is seen on the feet, it has become very severe.</li>
                <li>Clinical features of jaundice- vomiting, inability to suck, features of failure to thrive, abdominal distension</li>
                <li>Colour of urine/stool</li>
                <li>Feeding history, weight loss</li>
                <li>Care so far</li>
                <li>Maternal history</li>
                <ul>
                  <li>Antenatalâ€” booking, illnesses, infections</li>
                  <li>Drugsâ€” sulfa, NSAIDS, herbals</li>
                  <li>Blood group (motherâ€™s and fatherâ€™s), haemolytic diseases, liver disease, recurrent jaundice</li>
                </ul>
                <li>Family historyâ€” siblings with jaundice, familial jaundice, liver disease</li>
                <li>Birth historyâ€” trauma, cord clamping</li>
               </ul>
            </div>
          </section>

          <section id='heading-6-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-2'>Physical Examinations</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Jaundice usually becomes apparent in a cephalocaudal progression, starting on the face and progressing to the abdomen and then the feet, as serum level increase.</li>
                <li>Pallor</li>
                <li>Dehydration</li>
                <li>Weight loss</li>
                <li>Fever or hypothermia</li>
                <li>Hepato/splenomegaly</li>
                <li>Evidence of birth trauma or injuries</li>
                <li>Evidence of kernicterus</li>
               </ul>
            </div>
          </section>

          <section id='heading-6-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-3'>Investigations</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Serum bilirubinâ€” total, conjugated</li>
                <li>Full blood count and blood smear</li>
                <li>Haemoglobin concentration</li>
                <li>Reticulocyte count</li>
                <li>Blood group</li>
                <li>Coombs test</li>
                <li>Urinalysis</li>
                <li>Urine m/c/s</li>
                <li>Electrolyte, urea and creatinine</li>
                <li>Liver function test (AST/ALT, ALP/GGT)</li>
                <li>G6PD assay</li>
                <li>Ultrasound </li>
                <li>Thyroid function test</li>
               </ul>
            </div>
          </section>

          <section id='heading-6-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-4'>Treatment</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Anticipatory care</li>
                <li>Phototherapy</li>
                <li>EBT</li>
               </ul>

               <figure>
                <img src="../figures/nn-hyperbili (2).png" alt="">
                <figcaption> Dermal Zones of Jaundice</figcaption>
              </figure>

              <h4>Phototherapy </h4>
              <ul>
                <li>An effective means of reducing serum bilirubin level</li>
                <li>Acts by converting extra-vascular (skin and cutaneous) bilirubin to less lipophilic products that diffuse back into the blood and can be excreted in the bile without the requirement for conjugation</li>
              </ul>

              <figure>
                <img src="../figures/nn-hyperbili (2).jpg" alt="">
                <figcaption> </figcaption>
              </figure>

              <p>Mechanism</p>
              <ul>
                <li>Yellow pigment absorbs light maximally at 450-460nm. Following absorption light reduces Bilirubin by </li>
                <li>Photo-oxidation</li>
                <ul>
                  <li>Occurs too slowly to be of clinical importance</li>
                </ul>
                <li>Configurational Photo-isomerization</li>
                <ul>
                  <li>Converts 4Z, 15Z bilirubin to photo-isomers (4Z, 15E), </li>
                </ul>
                <li>Structural Photo-isomerization</li>
                <ul>
                  <li>Irreversible formation of Lumirubin, which is excreted unchanged in bile and urine</li>
                </ul>
              </ul>
              <p>Indication</p>
              <ul>
                <li>To prevent the need for EBT</li>
                <li>Hence 2/3rd of projected Exchange value</li>
              </ul>
              <p>Type of light</p>
              <ul>
                <li>Narrow Spectrum (special blue lights)</li>
                <li>May also use green light</li>
                <ul>
                  <li>Both lights obscure assessment of cyanosis, jaundice and causes discomfort to the staff</li>
                </ul>
              </ul>
              <p>When to stop</p>
              <ul>
                <li>Once indication for its use has been averted</li>
              </ul>
              <p>Side Effects</p>
              <ul>
                <li>Diarrhoea </li>
                <li>Skin rashes</li>
                <li>Temperature instability</li>
                <li>Dehydration</li>
                <li>Retinal damage</li>
                <li>Eye injury & nasal occlusion from bandages</li>
                <li>Bronze Baby Syndrome</li>
                <ul>
                  <li>Infants with conjugated hyperbilirubinaemia</li>
                </ul>
              </ul>

              <h4>Exchange Blood Transfusion</h4>
              <p>Objective</p>
              <ul>
                <li>To Prevent Bilirubin Encephalopathy</li>
              </ul>
              <p>Determinants of when</p>
              <ul>
                <li>Level of unconjugated bilirubin</li>
                <ul>
                  <li>â‰¥20mg/dl or 342umol/l in term babies</li>
                  <li>Rule of 10 in preterms (10 x bt wt in kg)</li>
                </ul>
                <li>Rate of rise of serum bilirubin</li>
                <ul>
                  <li>No magic figure but serves as guide for projecting the need for EBT</li>
                </ul>
                <li>Clinical condition of the patient</li>
                <ul>
                  <li>HIE, Acidosis, prolonged hypothermia</li>
                </ul>
              </ul>
              <p>EBT Complications</p>
              <ul>
                <li>Catheter </li>
                <ul>
                  <li>Air embolism, gut perforation</li>
                  <li>Arrhythmia</li>
                  <li>Infection, NEC</li>
                </ul>
                <li>Procedure</li>
                <ul>
                  <li>Hypothermia, Hypovolaemia/hypervolaemia</li>
                </ul>
                <li>Blood</li>
                <ul>
                  <li>Transmission of organisms </li>
                  <li>Hyperkalaemia</li>
                  <li>Hypocalcaemia</li>
                  <li>Blood incompatibility</li>
                  <li>Hypoglycaemia </li>
                </ul>
              </ul>

              <h4>Management of Conjugated Hb</h4>
              <ul>
                <li>Surgical hyperbilirubinemia</li>
                <li>Investigations; LFT, ABD USS</li>
                <li>Specific treatment depends on the cause</li>
                <ul>
                  <li>Kasai procedure for biliary atresia</li>
                </ul>
              </ul>
            </div>
          </section>
        </div>
      </section>



      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <div class="comment">
        <p>Send your comments, corrections, explanations/clarifications and requests/suggestions to our <a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">WhatsApp group</a>.</p>
        </div>
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The content on this â€˜Websiteâ€™, including but not limited to text, graphics, images, videos, and other materials, should not be considered as a substitute for formal medical education or clinical training. The creators and operators of this Website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the Website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this Website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>     
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
          <p><a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">say hiðŸ‘‹</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
</body>
</html>
 
